Pancreatic neuroendocrine tumors: A focus on the current classification and molecular targeted therapy

Michela Squadroni, Vincenzo Formica, Giovanni di Meglio, Cristina Dealis, Francesca Spada, Katia Lorizzo, Nicola Fazio

Research output: Contribution to journalArticle

Abstract

Although their incidence has been rising over the last decades, pancreatic neuroendocrine tumors (PNETs) are relatively uncommon, accounting for less than 5% of all primary pancreatic malignancies. They are classified based on morphological and biological characteristics. The World Health Organization (WHO) classification from 2000 subcategorizes gastroenteropancreatic neuroendocrine tumors into welldifferentiated tumors, well-differentiated carcinomas, and poorly differentiated carcinomas; the TNM staging system from 2006 considers three "G" groups based on the Ki-67 level and three "T" groups related to the size. Retrospective analyses confirmed the prognostic relevance of both WHO and TNM staging systems for PNETs. As for treatment, chemotherapy, somatostatin analogs, interferon, and peptide radioreceptor therapy can have a role in PNETs. Over the last decade several molecular targeted agents have been studied. Among them sunitinib and everolimus are in the most advanced phase of clinical investigation. This is a literature review, based on a Medline search for pancreatic neuroendocrine tumor and carcinoma, which will focus on the clinical importance of classifications and the advances of molecular targeted therapies in PNETs.

Original languageEnglish
JournalEuropean journal of Clinical and Medical Oncology
Volume2
Issue number2
Publication statusPublished - 2010

Fingerprint

Molecular Targeted Therapy
Neuroendocrine Tumors
Neoplasm Staging
Carcinoma
Neuroendocrine Carcinoma
Somatostatin
Interferons
Neoplasms
Drug Therapy
Peptides
Incidence
Therapeutics

Keywords

  • Everolimus
  • Grading system
  • Pancreatic neuroendocrine tumor
  • Sunitinib
  • TNM
  • WHO classification

ASJC Scopus subject areas

  • Oncology

Cite this

Pancreatic neuroendocrine tumors : A focus on the current classification and molecular targeted therapy. / Squadroni, Michela; Formica, Vincenzo; di Meglio, Giovanni; Dealis, Cristina; Spada, Francesca; Lorizzo, Katia; Fazio, Nicola.

In: European journal of Clinical and Medical Oncology, Vol. 2, No. 2, 2010.

Research output: Contribution to journalArticle

Squadroni, Michela ; Formica, Vincenzo ; di Meglio, Giovanni ; Dealis, Cristina ; Spada, Francesca ; Lorizzo, Katia ; Fazio, Nicola. / Pancreatic neuroendocrine tumors : A focus on the current classification and molecular targeted therapy. In: European journal of Clinical and Medical Oncology. 2010 ; Vol. 2, No. 2.
@article{09aeb9c3b4e54a869534a36d91974777,
title = "Pancreatic neuroendocrine tumors: A focus on the current classification and molecular targeted therapy",
abstract = "Although their incidence has been rising over the last decades, pancreatic neuroendocrine tumors (PNETs) are relatively uncommon, accounting for less than 5{\%} of all primary pancreatic malignancies. They are classified based on morphological and biological characteristics. The World Health Organization (WHO) classification from 2000 subcategorizes gastroenteropancreatic neuroendocrine tumors into welldifferentiated tumors, well-differentiated carcinomas, and poorly differentiated carcinomas; the TNM staging system from 2006 considers three {"}G{"} groups based on the Ki-67 level and three {"}T{"} groups related to the size. Retrospective analyses confirmed the prognostic relevance of both WHO and TNM staging systems for PNETs. As for treatment, chemotherapy, somatostatin analogs, interferon, and peptide radioreceptor therapy can have a role in PNETs. Over the last decade several molecular targeted agents have been studied. Among them sunitinib and everolimus are in the most advanced phase of clinical investigation. This is a literature review, based on a Medline search for pancreatic neuroendocrine tumor and carcinoma, which will focus on the clinical importance of classifications and the advances of molecular targeted therapies in PNETs.",
keywords = "Everolimus, Grading system, Pancreatic neuroendocrine tumor, Sunitinib, TNM, WHO classification",
author = "Michela Squadroni and Vincenzo Formica and {di Meglio}, Giovanni and Cristina Dealis and Francesca Spada and Katia Lorizzo and Nicola Fazio",
year = "2010",
language = "English",
volume = "2",
journal = "European journal of Clinical and Medical Oncology",
issn = "1759-8958",
publisher = "San Lucas Medical",
number = "2",

}

TY - JOUR

T1 - Pancreatic neuroendocrine tumors

T2 - A focus on the current classification and molecular targeted therapy

AU - Squadroni, Michela

AU - Formica, Vincenzo

AU - di Meglio, Giovanni

AU - Dealis, Cristina

AU - Spada, Francesca

AU - Lorizzo, Katia

AU - Fazio, Nicola

PY - 2010

Y1 - 2010

N2 - Although their incidence has been rising over the last decades, pancreatic neuroendocrine tumors (PNETs) are relatively uncommon, accounting for less than 5% of all primary pancreatic malignancies. They are classified based on morphological and biological characteristics. The World Health Organization (WHO) classification from 2000 subcategorizes gastroenteropancreatic neuroendocrine tumors into welldifferentiated tumors, well-differentiated carcinomas, and poorly differentiated carcinomas; the TNM staging system from 2006 considers three "G" groups based on the Ki-67 level and three "T" groups related to the size. Retrospective analyses confirmed the prognostic relevance of both WHO and TNM staging systems for PNETs. As for treatment, chemotherapy, somatostatin analogs, interferon, and peptide radioreceptor therapy can have a role in PNETs. Over the last decade several molecular targeted agents have been studied. Among them sunitinib and everolimus are in the most advanced phase of clinical investigation. This is a literature review, based on a Medline search for pancreatic neuroendocrine tumor and carcinoma, which will focus on the clinical importance of classifications and the advances of molecular targeted therapies in PNETs.

AB - Although their incidence has been rising over the last decades, pancreatic neuroendocrine tumors (PNETs) are relatively uncommon, accounting for less than 5% of all primary pancreatic malignancies. They are classified based on morphological and biological characteristics. The World Health Organization (WHO) classification from 2000 subcategorizes gastroenteropancreatic neuroendocrine tumors into welldifferentiated tumors, well-differentiated carcinomas, and poorly differentiated carcinomas; the TNM staging system from 2006 considers three "G" groups based on the Ki-67 level and three "T" groups related to the size. Retrospective analyses confirmed the prognostic relevance of both WHO and TNM staging systems for PNETs. As for treatment, chemotherapy, somatostatin analogs, interferon, and peptide radioreceptor therapy can have a role in PNETs. Over the last decade several molecular targeted agents have been studied. Among them sunitinib and everolimus are in the most advanced phase of clinical investigation. This is a literature review, based on a Medline search for pancreatic neuroendocrine tumor and carcinoma, which will focus on the clinical importance of classifications and the advances of molecular targeted therapies in PNETs.

KW - Everolimus

KW - Grading system

KW - Pancreatic neuroendocrine tumor

KW - Sunitinib

KW - TNM

KW - WHO classification

UR - http://www.scopus.com/inward/record.url?scp=77956277391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956277391&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77956277391

VL - 2

JO - European journal of Clinical and Medical Oncology

JF - European journal of Clinical and Medical Oncology

SN - 1759-8958

IS - 2

ER -